Valion Bio Inc (VBIO) Income Statement
VBIO 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsVBIO revenue and net income
Where VBIO's revenue goes
2025Each bar shows an amount and its share of revenue. VBIO kept −2,324.1% of revenue as net income.
VBIO profit margins
VBIO growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | −40.8% | −15.0% | +4.5% |
| Gross profit | — | −52.5% | — | −12.7% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
VBIO quarterly EPS vs estimates
Next report: November 13, 2026.
VBIO income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $382,000 | $0 | $1.2M | $1.8M | $1.3M | $860,000 | $420,000 | $102,420 | $163,360 | $248,350 |
| Cost of revenue | $350,000 | $352,000 | $889,000 | $1.5M | $1.3M | $1.1M | $713,000 | $77,940 | $108,260 | $149,480 |
| Gross profit | $32,000 | −$352,000 | $287,000 | $299,000 | −$46,000 | −$233,000 | −$293,000 | $24,480 | $55,100 | $98,870 |
| Research & development | $3.1M | $1.3M | $1.7M | $1.7M | $870,000 | $768,000 | $986,000 | $1.9M | $893,960 | $613,120 |
| Sales, general & admin | $4.8M | $3.2M | $6.9M | $8.7M | — | $1.9M | $2.7M | $2.5M | $2.6M | $2.2M |
| Total operating expenses | $7.9M | $4.1M | $8.5M | $10.4M | $5.6M | $3.1M | $3.4M | $4.4M | $3.5M | $2.8M |
| Operating income | −$7.9M | −$4.4M | −$8.2M | −$10.1M | −$5.6M | −$3.3M | −$3.6M | −$4.4M | −$3.5M | −$2.7M |
| Interest income | $23,000 | $6,000 | $1,000 | $2,000 | — | — | — | — | — | — |
| Interest expense | $146,000 | $0 | — | — | $1.8M | $423,000 | $443,000 | — | $1,010 | $363 |
| Income before taxes | −$8.0M | −$4.5M | −$8.2M | −$10.1M | −$8.5M | −$3.6M | −$4.1M | −$4.3M | −$5.2M | −$141,330 |
| Income taxes | — | — | — | — | — | — | $2,000 | — | — | — |
| Net income | −$8.9M | −$5.7M | −$8.2M | −$10.1M | −$8.5M | −$3.6M | −$4.1M | −$4.3M | −$5.2M | −$141,330 |
| EBITDA | −$7.8M | −$4.1M | −$8.1M | −$9.9M | −$5.6M | −$3.3M | −$3.6M | −$4.3M | −$5.2M | −$140,967 |
| EPS (diluted) | −$39.95 | −$727.55 | −$5469.38 | −$11193.04 | −$16290.91 | — | −$0.08 | −$0.19 | −$0.35 | −$0.02 |
| Gross margin | 8.4% | — | 24.4% | 16.2% | −3.7% | −27.1% | −69.8% | 23.9% | 33.7% | 39.8% |
| Operating margin | −2,067.5% | — | −701.1% | −548.8% | −448.1% | −386.2% | −867.4% | −4,292.9% | −2,125.1% | −1,104.0% |
| Net margin | −2,324.1% | — | −701.0% | −548.7% | −675.7% | −423.1% | −987.6% | −4,207.2% | −3,195.0% | −56.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $915,380 | $0 | $146,000 | $86,000 | $0 | $180,000 | $126,000 | $140,000 | $334,000 | $357,000 | $282,000 |
| Cost of revenue | $358,000 | — | $302,000 | $291,000 | $32,000 | $1,000 | $419,000 | $83,000 | $111,000 | $168,000 | $354,000 | $174,000 |
| Gross profit | −$358,000 | — | −$302,000 | −$145,000 | $54,000 | −$1,000 | −$239,000 | $43,000 | $29,000 | $166,000 | $2,999 | $108,000 |
| Research & development | $2.3M | $1.9M | $1.3M | $858,000 | $655,000 | $335,000 | $333,000 | $421,000 | $301,000 | $255,000 | $358,000 | $337,000 |
| Sales, general & admin | $526,743 | $3.8M | $1.8M | $1.5M | $1.3M | $1.0M | $971,000 | — | — | — | — | — |
| Total operating expenses | $6.1M | $5.6M | $1.7M | $2.3M | $2.0M | $1.4M | $1.3M | $1.5M | $1.2M | $1.6M | $2.2M | $1.9M |
| Operating income | −$6.4M | −$5.6M | −$2.0M | −$2.5M | −$1.9M | −$1.4M | −$1.5M | −$1.4M | −$1.2M | −$1.5M | −$2.2M | −$1.8M |
| Interest income | $11,000 | $24,000 | $12,000 | $4,000 | $3,000 | $4,000 | — | — | — | — | — | — |
| Interest expense | $691,000 | $648,000 | — | $38,245 | $0 | $0 | — | — | — | — | — | — |
| Income before taxes | −$7.1M | −$6.2M | −$2.0M | −$2.6M | −$1.9M | −$1.4M | −$1.5M | −$1.4M | −$1.3M | −$1.5M | −$2.2M | −$1.8M |
| Net income | −$7.1M | −$6.2M | −$2.8M | −$2.6M | −$1.9M | −$1.5M | −$1.5M | −$1.4M | −$1.3M | −$1.5M | −$2.2M | −$1.8M |
| EBITDA | −$6.1M | −$5.4M | −$1.9M | −$2.5M | −$1.9M | −$1.4M | −$1.3M | −$1.4M | −$1.2M | −$1.4M | −$2.2M | −$1.7M |
| EPS (diluted) | −$2.17 | −$53.77 | — | −$49.14 | −$54.78 | −$2.52 | −$66.30 | −$98.23 | −$134.19 | −$428.84 | −$650.22 | −$25.16 |
| Gross margin | −32.3% | — | — | −99.3% | 62.8% | — | −132.8% | 34.1% | 20.7% | 49.7% | 0.8% | 38.3% |
| Operating margin | −578.9% | −615.5% | — | −1,700.7% | −2,248.8% | — | −857.2% | −1,135.7% | −861.4% | −443.4% | −628.6% | −624.1% |
| Net margin | −640.1% | −677.5% | — | −1,778.1% | −2,245.3% | — | −820.6% | −1,135.7% | −904.3% | −443.4% | −628.3% | −624.1% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in VBIO's financial statements (latest annual report filed March 30, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
VBIO financial results
In fiscal year 2025 (ended December 31, 2025), Valion Bio reported revenue of $0.4 million. It had a net loss of $8.9 million, a net profit margin of −2,324.1%. Diluted earnings per share came to −$39.95. Over five years revenue grew at an average rate of −15.0% a year.
See the VBIO stock overview for the latest quote and news, or the VBIO chart for price history and technical indicators.
VBIO income statement FAQ
What is Valion Bio's annual revenue?
Valion Bio reported total revenue of $0.4 million for fiscal year 2025, which ended on December 31, 2025.
Is Valion Bio profitable?
No. Valion Bio reported a net loss of $8.9 million in fiscal 2025, a net profit margin of −2,324.1%; its operating margin was −2,067.5%.
What is Valion Bio's gross margin?
Valion Bio's gross margin was 8.4% in fiscal 2025: for every $100 of revenue, Valion Bio kept $8 after the direct cost of its products and services.
How much does Valion Bio spend on research and development?
Valion Bio spent $3.1 million on research and development in fiscal 2025, 819.6% of revenue.
How fast is Valion Bio growing?
Revenue grew −15.0% a year on average over the last five fiscal years, from $0.9 million to $0.4 million.
What are Valion Bio's earnings per share?
Valion Bio earned $-39.95 per diluted share in fiscal 2025, compared with $-727.55 a year earlier.
When will Valion Bio report its next earnings?
Valion Bio is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
When does Valion Bio's fiscal year end?
Valion Bio's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 30, 2026.